Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCR201 in Parkinson's Disease
NCT06978920Phase 1Recruiting
- Sponsor
- Nuwacell Biotechnologies
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of Universal iDAP in Parkinson's disease (PD) (2 arms), sponsored by Nuwacell Biotechnologies. Primary endpoint: Incidence and severity of adverse events at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
Universal iDAP
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06978920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978920.